AIM ImmunoTech Videos

AIM ImmunoTech News

AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points...

Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt...

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s®...

Announces new ticker symbol ‘AIM’ effective September 3, 2019 OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech...

AIM ImmunoTech Articles

Hemispherx Bio up 22% on Ampligen + Keytruda studies: SeekingAlpha

Thinly traded nano cap Hemispherx Biopharma (HEB +22.1%) is up on a 7x surge in volume in reaction to its announcement of two clinical...
381cf01438895cab0b3756fba2d0131142708ac5e7aa3f1832